




Patent Docket P0706P2C2D2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of James Lee et al. Serial No.: 10/666,689 Filed: September 19, 2003 For: HUMAN PF4A RECEPTORS, NUCLEIC ACID ENCODING AND ANTIBODIES BINDING THERETO	Group Art Unit: 1646 Examiner: not yet assigned Confirmation No: 2217 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 9, 2004  Christine Ricks
--	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information listed on the attached revised Form PTO-1449 of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/104,063, filed June 24, 1998 and relied upon in this application for an earlier filing date under 35 USC §120.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

Serial No. 10/666,689

- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).


The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: January 9, 2004

By:



Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0706P2C2D2C1Serial No.
10/666,689

LIST OF DISCLOSURES OF THE APPLICANT

(Use several sheets if necessary)

Applicant
Lee et al.Filing Date
19 Sep 2003Group
1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	5,374,506	20.12.94	Murphy, P.			
	* 2	5,543,503	06.08.96	Chuntharapai et al.			11.06.93

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	3	WO 92/04372	19.03.92	PCT				
	* 4	WO 92/17497	15.10.92	PCT				
	* 5	WO 92/18641	29.10.92	PCT				
	* 6	WO 93/06229	01.04.93	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 7	Antibodies: A Laboratory Manual (Chapter 5), Harlow and Lane, eds., Cold Spring Harbor Laboratory pps. 72-76 (1988)						
	* 8	Beckmann et al., "Molecular characterization of the interleukin-8 receptor" <u>Biochem. & Biophys. Res. Comm.</u> 179(2):784-789 (Sep 16, 1991)						
	* 9	Besemer et al., "Specific Binding, Internalization, and Degradation of Human Neutrophil Activating Factor by Human Neutrophil Activating Factor by Human Polymorphonuclear Leukocytes" <u>Journal of Biological Chemistry</u> 264:17409-17415 (1989)						
	*10	Bleul et al., "The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes" <u>Proc. Natl. Acad. Sci. USA</u> 94:1925-1930 (March 1997)						
	*11	Boulay et al., "Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA" <u>Biochem. Biophys Res. Comm.</u> 168(3):1103-1109 (1990)						
	12	Brennan et al., "Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells" <u>European Journal of Immunology</u> 20:2141-2144 (1990)						
	*13	Broadus et al., "Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema" <u>Amer. Rev. Resp. Disease</u> 146:825-830 (1992)						
	*14	Chuntharapai et al., "Generation and characterization of monoclonal antibodies (mAbs) to human IL 8 receptor A" <u>J. Immunol.</u> (abstract #708) 150(8(2)):126A (May 1993)						
	*15	Chuntharapai et al., "Neutralizing monoclonal antibodies to human IL-8 receptor A map to the NH ₂ -terminal region of the receptor" <u>J. Immunol.</u> 152(4):1783-1789 (1994)						
	*16	Clark-Lewis et al., "Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg" <u>Proc. Natl. Acad. Sci. USA</u> 90(8):3574-3577 (Apr 15, 1993)						
	*17	Clark-Lewis et al., "Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs" <u>Journal of Biological Chemistry</u> 266(34):23128-23134 (1991)						
	18	Crockard et al., "Markers of Inflammatory Activation: Upregulation of Complements Receptors CR1 and CR3 on Synovial Fluid Neutrophils from Patients with Inflammatory Joint Disease" <u>Clinical Immunol. & Immunopath.</u> 65(2):135-142 (1992)						
	*19	D'Andrea et al., "Expression Cloning of the Murine Erythropoietin Receptor" <u>Cell</u> 57:277-285 (1989)						
	20	DeForge et al., "Interleukin-1 Receptor Antagonist Protein Inhibits Interleukin-8 Expression in Lipopolysaccharide-stimulated Human Whole Blood" <u>Amer. J. Path.</u> 140(5):1045-1054 (1992)						

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0706P2C2D2C1Serial No.
10/666,689

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Lee et al.

Filing Date

19 Sep 2003

Group

1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

21	DeForge et al., "Oxygen Radical Scavengers Selectively Inhibit Interleukin 8 Production in Human Whole Blood" <u>J. Clin. Invest.</u> 90(5):2123-2129 (1992)
22	Deleuran et al., "The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells" <u>Cytokine</u> 4(5):403-409 (1992)
23	Dinareello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome" <u>Journal of the American Medical Assn.</u> 269(14):1829-1835 (1991)
*24	Dixon et al., "Structural features required for ligand binding to the -adrenergic receptor" <u>EMBO Journal</u> 6(11):3269-3275 (1987)
*25	Dixon, et al., "Structure-Function Analysis of the Beta-Adrenergic Receptor" <u>Cold Spring Har. Sym. Quant. Biol.</u> 53:487-497 (1988)
*26	Federspiel et al., "Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen" <u>Genomics</u> 16:707-712 (1993)
*27	Feng, Yu et al., "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor" <u>Science</u> 272:872-877 (1996)
*28	Gayle III et al., "Importance of the Amino Terminus of the Interleukin-8 Receptor in Ligand Interactions" <u>Journal of Biological Chemistry</u> 268(10):7283-7289 (1993)
29	Gearing et al., "Expression Cloning of a Receptor for Human Granulocyte-macrophage Colony-stimulating Factor" <u>EMBO Journal</u> 8(12):3667-3676 (1989)
*30	Gerard & Gerard, "The chemotactic receptor for human C5a anaphylatoxin" <u>Nature</u> 349:614-617 (1991)
*31	Grob et al., "Characterization of a Receptor for Human Monocyte-derived Neutrophil Chemotactic Factor/Interleukin-8" <u>Journal of Biological Chemistry</u> 265(14):8311-8316 (1990)
32	Gryniewicz et al., "A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties" <u>Journal of Biological Chemistry</u> 260(6):3440-3450 (1985)
*33	Hammond et al., "Generation of neutralizing antibodies to human interleukin-8 (IL8) receptors" <u>J. Cell Biochem.</u> (Suppl. 18B) 318:Abstract #0108 (1994)
*34	Harada et al. <u>Gene</u> 142:297-300 (1994)
*35	Hebert et al., "Endothelial and Leukocyte Forms of IL-8: Conversion by Thrombin and Interactions with Neutrophils" <u>J. Immunol.</u> 145(9):3033-3040 (Nov 1, 1990)
*36	Hebert et al., "Partial functional mapping of the human interleukin-8 type A receptor" <u>Journal of Biological Chemistry</u> 268(25):18549-18553 (1993)
*37	Hebert et al., "Scanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Receptor Binding" <u>Journal of Biological Chemistry</u> 266(28):18989-18994 (1991)
38	Hemmi et al., "A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells" <u>Cell</u> 76:803-810 (1994)
*39	Herzog et al., "Molecular cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: lack of NPY binding and activation" <u>DNA and Cell Biology</u> 12(6):465-471 (1993)
40	Hirota et al., "Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor" <u>Rheumatol. Int.</u> 12:13-16 (1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0706P2C2D2C1Serial No.
10/666,689

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)

Applicant
Lee et al.Filing Date
19 Sep 2003Group
1646**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

*41	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
42	Horuk et al., "Purification, Receptor Binding Analysis, and Biological Characterization of Human Melanoma Growth Stimulating Activity (MGSA)" <u>Journal of Biological Chemistry</u> 268(1):541-546 (1993)
*43	Jazin et al., "A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells" <u>Regulatory Peptides</u> 47:247-258 (1993)
*44	Kahan, "Immunosuppressive therapy" <u>Current Opinion in Immunology</u> 4(5):553-560 (Oct 1992)
45	Keller, G. H. et al., "Molecular Hybridization Technology" <u>DNA Probes</u> , New York, NY:Stockton Press pps. xv-xvi; 2-27 (1989)
*46	Koch et al., "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis" <u>Science</u> 258:1798-1801 (1992)
47	Koch et al., "Interleukin-8 is a potent human macrophage-derived mediator of angiogenesis that is blocked by interleukin-8 antibody and antisense oligonucleotide" <u>Arthritis and Rheumatism</u> (abstract #86) 35(9 Supp.):S49 (1992)
*48	Koch et al., "Synovial tissue macrophage as a source of the chemotactic cytokine IL-8" <u>J. Immunol.</u> 147(7):2187-2195 (1991)
*49	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor" <u>Nature</u> 323:411-416 (1986)
*50	LaRosa et al., "Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity" <u>Journal of Biological Chemistry</u> 267(35):25402-25406 (1992)
*51	Lee et al., "Characterization of Complementary DNA Clones Encoding the Rabbit IL-8 Receptor" <u>Journal of Immunology</u> 148(4):1261-1264 (Feb 15, 1992)
*52	Lee et al., "Characterization of Two High Affinity Human Interleukin-8 Receptors" <u>Journal of Biological Chemistry</u> 267(23):16283-16287 (1992)
*53	Lerner, R.A., "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity" <u>Nature</u> 299:592-596 (Oct 1982)
*54	Lindley et al., "NAP-1/IL-8 in Rheumatoid Arthritis" <u>Advances in Experimental Medicine and Biology</u> (Chemotactic Cytokines: Biology of the Inflammatory Peptide Supergene Family), Westwick, J. et al.(eds) Vol. 305:147-156 (1991)
*55	Loetscher et al., "Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes" <u>Journal of Biological Chemistry</u> 269(1):232-237 (1994)
*56	Mahida et al., "Enhanced synthesis of neutrophil-activating peptide-I/interleukin-8 in active ulcerative colitis" <u>Clinical Science</u> 82:273-275 (1992)
57	Mattoli et al., "Expression of the Potent Inflammatory Cytokines, GM-CSF, IL6, and IL8, in Bronchial Epithelial Cells of Asthmatic Patients" 101(3):27S-29S (1992)
*58	Moser et al., "Interleukin-8 Antagonists Generated by N-terminal Modification" <u>Journal of Biological Chemistry</u> 268(10):7125-7128 (1993)
*59	Murphy and Tiffany, "Cloning of complementary DNA encoding a functional human interleukin-8 receptor" <u>Science</u> 253(5025):1280-1283 (Sep 13, 1991)
*60	Nomura, H. et al., "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors" <u>International Immunology</u> 5(10):1239-1249 (1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P0706P2C2D2C1

Serial No.

10/666,689

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Lee et al.

Filing Date

19 Sep 2003

Group

1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*61	Oppenheim et al., "Properties of the novel proinflammatory supergene intericine" cytokine family" <u>Annu. Rev. Immunol.</u> 9:617-648 (1991)
62	Peichl et al., "Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis" <u>Annals Rheum. Dis.</u> 51:19-22 (1992)
*63	Peralta et al., "Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors" <u>EMBO Journal</u> 6:3923-3929 (1987)
64	Porat et al., "Interleukin-1 (IL-1) receptor blockade reduces endotoxin and Borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells" <u>FASEB J.</u> 6(7):2482-2486 (1992)
*65	Prado et al. <u>Journal of Biological Chemistry</u> 269(17):12391-12394 (April 29, 1994)
*66	Quan, J.M. et al., "Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis" <u>Biochem. & Biophys. Res. Comm.</u> 219:405-411 (1996)
*67	Ramachandran et al., "The Structural and Functional Interrelationships of Muscarinic Acetylcholine Receptor Subtypes" <u>Bioessays</u> 10:54-57 (1989)
68	Rampart et al., "Development and Application of a Radioimmunoassay for Interleukin-8: Detection of Interleukin-8 Synovial Fluids from Patients with Inflammatory Joint Disease" <u>Laboratory Investigations</u> 66(4):512-518 (1992)
*69	Samanta et al., "Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils" <u>Journal of Experimental Medicine</u> 169:1185-1189 (1989)
*70	Saragovi et al., "The Murine Interleukin 2 Receptor: Irreversible Cross-Linking of Radiolabeled Interleukin 2 to High Affinity Interleukin 2 Receptors Reveals a Noncovalently Associated Subunit" <u>J. Immunol.</u> 139(6):1918-1926 (Sep. 15, 1987)
71	Seitz et al., "Enhanced Production of Neutrophil-activating Peptide-1/Interleukin-8 in Rheumatoid Arthritis" <u>J. Clin. Invest.</u> 87(2):463-469 (1991)
72	Seitz et al., "Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate" <u>Rheumatology</u> 12:159-164 (1992)
*73	Sevier et al., "Monoclonal Antibodies in Clinical Immunology" <u>Clinical Chemistry</u> 27(11):1797-1806 (1981)
*74	Sims et al., "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily" <u>Science</u> 241:585-589 (1988)
75	Smyth et al., "IL-8 Gene Expression and Production in Human Peripheral Blood Lymphocyte Subsets" <u>J. Immunol.</u> 146(11):3815-3823
76	Soh et al., "Identification and Sequence of an Accessory Factor Required for Activation of the Human Interferon γ Receptor" <u>Cell</u> 76:793-802 (1994)
*77	Sticherling et al., "Production and Characterization of Monoclonal Antibodies Against the Novel Neutrophil Activating Peptide NAP/IL-8" <u>J. Immunol.</u> 143(5):1628-1634 (September 1, 1989)
*78	Strader et al., "Structural basis of α -adrenergic receptor function" <u>FASEB</u> 3:1825-1832 (1989)
*79	Taylor, C. W., "The role of G proteins in transmembrane signalling" <u>Biochemical Journal</u> 272(1):1-13 (1990)
*80	Terkeltaub et al., "Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation" <u>Arthr. and Rheum.</u> 34:894-903 (1991)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 12 2004

Atty Docket No.
P0706P2C2D2C

Serial No.
10/666,689

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Lee et al.

Filing Date
19 Sep 2003

Group
1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.